IBOV 166,708.04 ▼ 0.14% IPSA 11,101.37 ▲ 0.53% IPC MEX 64,152.21 ▼ 0.38% MERVAL 2,947,349 ▼ 1.77% COLCAP 2,452.46 ▲ 0.84% BVL PERÚ 58,104.31 ▲ 0.40% USD/BRL5.20▼ 0.44% USD/MXN17.03▲ 0.06% USD/CLP914.59▼ 0.05% USD/COP3,133▼ 0.03% USD/PEN3.36▼ 0.36% USD/ARS1,488▼ 0.02% USD/UYU40.33▲ 0.01% USD/PYG5,997▲ 0.22% USD/BOB11.50▼ 0.35% USD/DOP58.55▲ 0.17% USD/CRC446.12— 0.00% USD/GTQ7.62▼ 0.05% USD/HNL26.79— 0.00% USD/NIO36.62— 0.00% USD/VES770.61▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.73▲ 0.41% EUR/BRL6.02▼ 0.42% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 166,708.04 ▼ 0.14% IPSA 11,101.37 ▲ 0.53% IPC MEX 64,152.21 ▼ 0.38% MERVAL 2,947,349 ▼ 1.77% COLCAP 2,452.46 ▲ 0.84% BVL PERÚ 58,104.31 ▲ 0.40% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Monday, August 17, 2026

Covid-19 Brazil

How Proposed Brazilian Nasal Spray Vaccine Against Covid-19 Could Work

By · January 18, 2021 · 2 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – A vaccine with no needle, no pain and no crying – this is the proposal of Brazilian scientists developing a nasal spray immunizer against the novel coronavirus. The vaccine, which has been under development since April 2020, has already shown good results in tests with mice and should be approved by the end of this year (if all goes well).

A vaccine with no needle, no pain and no crying - this is the proposal of Brazilian scientists developing a nasal spray immunizer against the novel coronavirus.
A vaccine with no needle, no pain and no crying – this is the proposal of Brazilian scientists developing a nasal spray immunizer against the novel coronavirus. (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

The concept of developing a spray vaccine was no accident. According to the head of research Jorge Elias Kalil Filho, the goal of the immunizer is to attack the virus at its gateway to the human body: the nasal mucosa.

To this end, researchers identified the most important targets of the immune response. “We see a better performance in a fragment of the spicule protein which is called the binding agent to the receptor [RBD], which is precisely the portion of the spicule protein that binds to the human cell receptor called ACE-2”, he says.

To develop the vaccine, 220 blood samples from people who recovered from the Covid-19 respiratory infection were investigated to understand which fragments of the coronavirus produced an immune response of T cells (responsible for the body’s defense) and which recognized and killed the infected cells.

Based on the studies, the scientists designed a hybrid artificial molecule with T-cell and RBD induction fragments. To carry this “blend” to the immune system, nanoparticles were developed in the laboratory.

The researchers’ goal is to develop a vaccine capable of making the human body produce the cellular and defense immune response, as well as generate a memory cell that will prevent the coronavirus from developing and reproducing after an infection – this is because, up to now, the memory created by the disease itself has not been proven to be lasting.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.